EMA Should Restrict Xeljanz and Ban Fenspiride, PRAC Advises

Drug Industry Daily
A A
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended limiting prescriptions of Xeljanz and cancelling fenspiride’s marketing authorization, citing safety concerns.

To View This Article:

Login

Subscribe To Drug Industry Daily